Analyses of prognostic factors for progression-free survival (PFS) in relation to age ≤60 vs. >60 years at autologous stem cell transplantation (ASCT) (a) and β₂-microglobulin≤3.5 vs. 3.5 mg/L at diagnosis (b), as well as depending on cytogenetic risk stratification at diagnosis (c).